![](/img/cover-not-exists.png)
Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
Xu, Zhijie, Wang, Xiang, Chen, Xi, Zeng, Shuangshuang, Gong, Zhicheng, Yan, YuanliangLanguage:
english
Journal:
Journal of Cell Communication and Signaling
DOI:
10.1007/s12079-020-00547-6
Date:
January, 2020
File:
PDF, 165 KB
english, 2020